NCT01677897已完成2 期
Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- progression free survival
研究概览
简要总结
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer
详细描述
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic chemotherapy-naive prostate cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Metastatic adenocarcinoma of the prostate.
- •Patient must give written informed consent before registration.
- •Age ≥18 years.
- •WHO performance status 0-
- •Tumor progression (as defined below) after at least 1 hormonal treatment (orchiectomy, LHRH agonist) with documented total testosterone levels ≤ 1.7 nmol/L (≤ 50 ng/dL). Ongoing concurrent use of LHRH agonist is required if the patient has not been surgically castrated.
- •PSA progression during treatment with abiraterone (at least 12 weeks of treatment) defined as follows:
- •In case PSA levels had not decreased under treatment: ≥ 25% increase over baseline (at registration) AND an increase in the absolute PSA value of ≥ 5 ng/mL.
- •In case of PSA response < 50% under treatment: ≥ 25% increase over the nadir AND an increase in the absolute PSA value of ≥ 5 ng/mL.
- •In case of PSA response ≥ 50% under treatment: ≥ 50% increase over the nadir AND an increase in the absolute PSA value of ≥ 5 ng/mL Note: PSA progression has to be confirmed at least 1 week later. In case of confirmation the first date of PSA rise is relevant for the calculation.
- •Serum potassium ≥ 3.5mmol/L.
- •Adequate hematological values: neutrophils ≥1.5x109/L, platelets ≥100x109/L.
- •Adequate hepatic function: bilirubin ≤1.5 x ULN, ALT ≤2.5 x ULN.
- •Adequate renal function (calculated creatinine clearance ≥50 mL/min, according to the formula of Cockcroft-Gault).
- •Able to swallow study drug as whole tablet.
- •Patient compliance and geographic proximity allow proper staging and follow-up.
排除标准
- •Previous malignancy within 2 years with the exception of localized non-melanoma skin cancer and Ta and Tis bladder cancer.
- •Known CNS or spinal cord metastases.
- •Active autoimmune disease requiring higher doses of corticosteroid than the equivalent of prednisone 10mg/d.
- •Radiotherapy within the last 2 weeks before start of the trial treatment.
- •Patients treated with anti-androgens such as flutamide or bicalutamide, if not discontinued at least 4 weeks prior to registration in case of response or in case of no response 2 weeks prior to inclusion for wash-out reasons.
- •Prior treatment with metformin Prior treatment with metformin
- •Diabetic ketoacidosis, diabetic coma and precoma
- •Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to trial entry, except treatment with bisphosphonates and LHRH agonists.
- •Known hypersensitivity to trial drugs or hypersensitivity to any of their components.
- •Concomitant drugs contraindicated for use with the trial drugs according to the Swissmedic-approved product information.
- •Uncontrolled hypertension, history of cardiac failure NYHA class III or IV.
- •Serious underlying medical condition (at the judgment of the investigator) which could impair the ability of the patient to participate in the trial (e.g. uncontrolled or acute severe infection, uncontrolled diabetes).
- •Active or symptomatic viral hepatitis or chronic liver disease.
- •History of pituitary or adrenal dysfunction.
- •Gastrointestinal disorder affecting absorption.
- •Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent, or interfering with compliance for oral drug intake.
研究组 & 干预措施
Metformin
Experimental
Metformin 2x1000mg orally per day
干预措施: Metformin (Drug)
结局指标
主要结局
progression free survival
时间窗: at 12 weeks
次要结局
- overall survival(up to 2 years)
研究者
Michael Mark
assistant medical director
Kantonsspital Graubünden
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Prostate CancerNCT04926155Sun Yat-sen University234
进行中（未招募）
2 期
The Effect of Metformin in Patients With Newly Diagnosed mHSPCMetastatic Prostate CancerNCT04925063Sun Yat-sen University266
终止
4 期
Effects of Metformin and Fish Oil on Treatment With ClozapineSchizo-affective DisorderSchizophreniaNCT02140788Duke University34
招募中
2 期
a clinical trial to study the effect of metformin and its correlation with vitamin d levels in patients with pulmonary fibrosisCTRI/2023/10/059325AIIMS New Delhi
已完成
3 期
Metformin as an adjunct therapy in mild-to-moderate ulcerative colitisUlcerative colitislcerative colitis.IRCT20181006041252N20Sabzevar University of Medical Sciences84